Evidence map›Paper›PMID 35298083›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2023

Waning locus coeruleus integrity precedes cortical tau accrual in preclinical autosomal dominant Alzheimer's disease.

Heidi I L Jacobs, John Alex Becker, Kenneth Kwong, Diana Munera, Liliana Ramirez-Gomez, Nina Engels-Domínguez, Justin S Sanchez, Clara Vila-Castelar, Ana Baena, Reisa A Sperling and 3 more

Open access · greenAbstract read
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
3.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 36 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Attenuated pupillary response during visual search in preclinical Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  5. The neuromodulatory fragility hypothesis of Alzheimer's disease pathogenesis.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  6. Sex differences in neuromodulatory subcortical systems and their implications for Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Evidence for a novel neuronal mechanism driving Alzheimer's disease, upstream of amyloid.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 3 countries.

Heidi I L JacobsGordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital/Harvard Medical School, Boston, Massachusetts, USA.
John Alex BeckerGordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital/Harvard Medical School, Boston, Massachusetts, USA.
Kenneth KwongAthinoula A. Martinos Center for Biomedial Imaging, Department of Radiology, Massachusetts General Hospital/Harvard Medical School, Boston, Massachusetts, USA.
Diana MuneraDepartment of Psychiatry, Massachusetts General Hospital/Harvard Medical School, Boston, Massachusetts, USA.
Liliana Ramirez-GomezDepartment of Neurology, Massachusetts General Hospital/Harvard Medical School, Boston, Massachusetts, USA.
Nina Engels-DomínguezGordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital/Harvard Medical School, Boston, Massachusetts, USA.
Justin S SanchezGordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital/Harvard Medical School, Boston, Massachusetts, USA.
Clara Vila-CastelarDepartment of Psychiatry, Massachusetts General Hospital/Harvard Medical School, Boston, Massachusetts, USA.
Ana BaenaGrupo Neurociencias de Antioquia, Universidad de Antioquia, Medellín, Colombia.
Reisa A SperlingAthinoula A. Martinos Center for Biomedial Imaging, Department of Radiology, Massachusetts General Hospital/Harvard Medical School, Boston, Massachusetts, USA.
Keith A JohnsonGordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital/Harvard Medical School, Boston, Massachusetts, USA.
Francisco LoperaGrupo Neurociencias de Antioquia, Universidad de Antioquia, Medellín, Colombia.
Yakeel T QuirozDepartment of Psychiatry, Massachusetts General Hospital/Harvard Medical School, Boston, Massachusetts, USA.
Massachusetts General Hospital · USUniversidad de Antioquia · COGordon Center for Medical Imaging · USHarvard University · USAthinoula A. Martinos Center for Biomedical Imaging · USBrigham and Women's Hospital · US

Funding

Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0M
TRIAL OF VALPROATE TO ATTENUATE THE PROGRESSION OF ADU01AG010483 · NIA · UNIVERSITY OF ROCHESTER · PI AISEN, PAUL S. · 1991 to 2012
$116.2M
RECRUITMENT COREU19AG010483 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FELDMAN, HOWARD · 2013 to 2020
$80.6M
Vascular factors, physical activity, and inflammation as modulators of neurodegenerative and cognitive trajectories (Project 2)P01AG036694 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI Rebecca E Amariglio · 2010 to 2026
$50.2M
THE ROLE OF ADVANCED CAA IN ALZHEIMER'S DEMENTIAP50AG005134 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI HYMAN, BRADLEY T. · 1985 to 2018
$42.1M
Research Education ComponentP30AG062421 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI Christine S Ritchie · 2019 to 2026
$36.5M
Evolution of memory-related fMRI activation over the course of MCI and ADR01AG027435 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI JOHNSON, KEITH A., SPERLING, REISA A. · 2006 to 2016
$8.6M
Tracking the origin of tau pathology: dovetailing (pre-)preclinical biomarker trajectoriesR01AG062559 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI Heidi Irma Jacobs · 2019 to 2026
$4.8M
The wandering nerve: gateway to boost Alzheimer's disease related cognitive performanceR01AG068062 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI JACOBS, HEIDI IRMA · 2021 to 2025
$4.6M
Disentangling the contribution of tau to aging and ADR01AG046396 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI JOHNSON, KEITH A. · 2014 to 2018
$4.0M
Relationship between tau pathology and cognitive impairment in autosomal dominant Alzheimer's diseaseR01AG054671 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI QUIROZ, YAKEEL T. · 2017 to 2021
$3.8M
Memory network dysfunction as an early marker of preclinical Alzheimer's DiseaseDP5OD019833 · OD · MASSACHUSETTS GENERAL HOSPITAL · PI QUIROZ, YAKEEL T. · 2014 to 2018
$2.3M
NIA NIH HHS P01 AG036694NIA NIH HHS P30 AG062421NIA NIH HHS P50 AG005134NIA NIH HHS R01 AG027435NIA NIH HHS R01 AG046396NIA NIH HHS R01 AG054671NIA NIH HHS R01 AG062559NIA NIH HHS R01 AG068062NIA NIH HHS R21 AG074220NIA NIH HHS U01 AG010483NIA NIH HHS U01 AG024904NIA NIH HHS U19 AG010483NIH HHS DP5 OD019833
6 · The paper itself

Abstract

introductionAutopsy studies recognize the locus coeruleus (LC) as one of the first sites accumulating tau in Alzheimer's disease (AD). Recent AD work related in vivo LC magnetic resonance imaging (MRI) integrity to tau and cognitive decline; however, relationships of LC integrity to age, tau, and cognition in autosomal dominant AD (ADAD) remain unexplored.

methodsWe associated LC integrity (3T-MRI) with estimated years of onset, cortical amyloid beta, regional tau (positron emission tomography [PET]) and memory (Consortium to Establish a Registry for Alzheimer's Disease (CERAD) Word-List-Learning) among 27 carriers and 27 non-carriers of the presenilin-1 (PSEN1) E280A mutation. Longitudinal changes between LC integrity and tau were evaluated in 10 carriers.

resultsLC integrity started to decline at age 32 in carriers, 12 years before clinical onset, and 20 years earlier than in sporadic AD. LC integrity was negatively associated with cortical tau, independent of amyloid beta, and predicted precuneus tau increases. LC integrity was positively associated with memory. DISCUSSION: These findings support LC integrity as marker of disease progression in preclinical ADAD.

Indexed as

Alzheimer DiseaseCognitive DysfunctionAdultAmyloid beta-PeptidesHumansLocus CoeruleusMutationPositron-Emission TomographyPresenilin-1tau ProteinsAmyloid beta-PeptidesPresenilin-1tau ProteinsAlzheimer's diseaseautosomal dominantbrainstemearly onsetlocus coeruleustau

Identifiers

PMID35298083
PMCPMC9481982
OpenAlexW4220785951

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.